Comprehensive clinical development programs being initiated for each investigational candidate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Innovent will supply sintilimab for the collaborated clinical trial
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
Furthering cell therapy ambition across oncology and autoimmune diseases
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Subscribe To Our Newsletter & Stay Updated
